Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | LPL | P06858 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594430 | 0.92 | ENPP2 (0.44) | ENPP2CA2LPLLIPGCA1 | |
| SCHEMBL1457390 | 0.87 | APP (0.33) | APP | |
| SCHEMBL2865496 | 0.83 | — | — | |
| SCHEMBL2866650 | 0.82 | ENPP2 (0.41) | ENPP2CA2LPLLIPGCA1 | |
| SCHEMBL30283030 | 0.72 | APP (0.44) | CA2CA1APP | |
| SCHEMBL2447287 | 0.72 | ENPP2 (0.48) | ENPP2CA2LPLLIPGCA1 | |
| SCHEMBL49312 | 0.71 | ENPP2 (0.55) | ENPP2CA2LPLLIPGCA1 | |
| SCHEMBL2866955 | 0.70 | CA1 (0.32) | CA2LPLLIPGCA1 | |
| SCHEMBL28247328 | 0.70 | GRM5 (0.45) | CA2CA1 | |
| SCHEMBL27034887 | 0.69 | CACNA2D1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | UGGT1, B3GAT3, UGCG | ENPP2 2127/4885CA2 4181/4885LPL 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.